Tuesday, July 7, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
ENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel IttodayCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First CallstodayENERGYWhy Constellation (CEG) Is Really a Policy Stock, Not a Utility Stock4 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct WinnerstodayCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger MarkettodayCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the PlaystodayENERGYWillow Isn't an Oil Play. It's an Interior Department Play.4 weeks agoTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail TradetodayCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade4 weeks agoCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest BeneficiariestodayENERGYWho Gets Exposed When the SPR Refill Never Happens4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR TherapeuticsyesterdayENERGYWashington Fixed the LNG Permit. It Can't Fix a County Courthouse in Guilford County.4 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting PaidyesterdayENERGYThe Jones Act's Hidden LNG Winner: Foreign Tankers, Not U.S. Shippers, Cash In4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironmentyesterdayCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model4 weeks agoTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public NamesyesterdayENERGYHalliburton vs. SLB: Who Actually Cashes In on Methane Compliance4 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Opens a Multi-Billion Dollar Market for Novo and LillyyesterdayENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.4 weeks agoDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense TradeyesterdayTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware4 weeks agoCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and RobinhoodyesterdayTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment2 days agoENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog4 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Suppliers2 days agoTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market2 days agoENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners4 weeks agoTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiaries2 days agoTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Story2 days agoTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Trade2 days agoENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock3 weeks agoCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling It3 days agoENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll3 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stocks3 days agoTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spot3 days agoDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First3 weeks agoWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiary3 days agoTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immune3 days agoDEFENSEThe Refueling Line Nobody Prices Into BWXT3 weeks agoTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Means3 days agoDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price3 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Win3 days agoENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers3 weeks agoHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payer3 days agoTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Market3 days agoDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat3 weeks agoDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expense4 days agoENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom3 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers4 days agoDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch3 weeks agoCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risk4 days agoDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivals4 days agoDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization3 weeks agoWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stack4 days agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market5 days agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch3 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwind5 days agoDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop3 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Tech5 days agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Moving5 days agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One3 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Money5 days agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money3 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boom5 days agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors3 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paid5 days agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus3 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Forever5 days agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI2 weeks agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock6 days agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive2 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers6 days agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime2 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch6 days agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending2 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political6 days agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub2 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending6 days agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington2 weeks agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game6 days agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics2 weeks agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risklast weekENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction2 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Tradelast weekDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet2 weeks agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Betlast weekDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratos2 weeks agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTXlast weekENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keys2 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligationlast weekDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguise2 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Streamlast weekDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Storylast weekDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sideslast weekENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own Itlast weekENERGYThe BLM Calendar That Moves COP and OXYlast weekDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machinelast weekDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Throughlast weekDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Orderlast weekDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivotlast weekDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Programlast weekENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primeslast weekDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differentlylast weekDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenlylast weekENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oillast week
That's your last free article this week. Create a free account for 2 a week — or go Pro for everything.Go Pro →
Healthcare & FDA

FDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market

Expanding the approved age to 2 years old roughly doubles the addressable patient pool for the only CRISPR-based gene therapy on the market.

Image: Money Racket
By at Money Racket · Jul 7, 2026

The FDA granted a supplemental approval for Casgevy (exagamglogene autotemcel) in patients as young as 2 years old with sickle cell disease or transfusion-dependent beta thalassemia. The therapy was previously limited to patients 12 and older.

Who cashes in: Casgevy is co-owned by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) — they split economics roughly 60/40. Sickle cell disease skews heavily pediatric; the median age of diagnosis is infancy, and the most severe disease burden falls on young children. Pushing the label down to age 2 meaningfully expands the commercial opportunity, since many families and physicians were waiting for pediatric data before committing to a one-time, six-figure treatment. Vertex is the larger, more liquid name and carries the commercial infrastructure; CRSP is the higher-beta play on the same catalyst. bluebird bio (BLUE) also has an approved gene therapy for sickle cell (Lyfgenia), so it competes for the same patients — but bluebird's financial position is fragile and it lacks Vertex's commercial reach.

Pushing the label to age 2 expands the addressable pool to the patients with the most severe disease burden — and Vertex holds the commercial keys.

Who's exposed: bluebird bio (BLUE) faces the clearest competitive pressure. Casgevy's CRISPR mechanism has generated strong safety data, and a younger label gives it first-mover advantage in the pediatric segment bluebird also targets. Hydroxyurea manufacturers and chronic transfusion programs at hospital systems face long-term volume erosion if gene therapy uptake accelerates, though that shift plays out over years, not quarters.

What to watch next: The real tell is payer coverage decisions — specifically whether major commercial insurers and Medicaid programs (which cover a disproportionate share of SCD patients) extend reimbursement to the 2-11 age cohort. Without coverage, the label expansion is largely symbolic. Watch Vertex's next earnings call for any commentary on treatment center capacity and patient pipeline in the pediatric segment.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →